UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
| PDL BIOPHarma, inc. |
|
(Name of Issuer)
|
| COMMON STOCK, PAR VALUE $0.01 PER SHARE |
|
(Title of Class of Securities) 69329Y104 |
|
(CUSIP Number)
|
| AUGUST 18, 2020 |
|
(Date of Event Which Requires Filing of this Statement)
|
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 69329Y104 | |||
| (1) Names of Reporting Persons | |||
| Park West Asset Management LLC | |||
| (2) Check the Appropriate Box if a Member of a Group | (a) [ ] | ||
| (b) [ ] | |||
| (3) SEC Use Only | |||
| (4) Citizenship or Place of Organization | |||
| Delaware | |||
| Number of Shares Beneficially Owned By Each Reporting Person With | |||
| (5) Sole Voting Power: | 0* | ||
| (6) Shared Voting Power: | 5,793,497* | ||
| (7) Sole Dispositive Power: | 0* | ||
| (8) Shared Dispositive Power: | 5,793,497* | ||
| (9) Aggregate Amount Beneficially Owned by Each Reporting Person | |||
| 5,793,497* | |||
| (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): | |||
| [ ] | |||
| (11) Percent of Class Represented by Amount in Row (9) | |||
| 5.1%* | |||
| (12) Type of Reporting Person | |||
| IA | |||
* See Item 4 for additional information.
| CUSIP No. 69329Y104 | |||
| (1) Names of Reporting Persons | |||
| Peter S. Park | |||
| (2) Check the Appropriate Box if a Member of a Group | (a) [ ] | ||
| (b) [ ] | |||
| (3) SEC Use Only | |||
| (4) Citizenship or Place of Organization | |||
| United States of America | |||
| Number of Shares Beneficially Owned By Each Reporting Person With | |||
| (5) Sole Voting Power: | 0* | ||
| (6) Shared Voting Power: | 5,793,497* | ||
| (7) Sole Dispositive Power: | 0* | ||
| (8) Shared Dispositive Power: | 5,793,497* | ||
| (9) Aggregate Amount Beneficially Owned by Each Reporting Person | |||
| 5,793,497* | |||
| (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): | |||
| [ ] | |||
| (11) Percent of Class Represented by Amount in Row (9) | |||
| 5.1%* | |||
| (12) Type of Reporting Person | |||
| IN | |||
* See Item 4 for additional information.
| Item 1(a). Name Of Issuer: PDL Biopharma, Inc., a Delaware corporation (the “Company”) | ||
| Item 1(b). Address of Issuer’s Principal Executive Offices: | ||
|
932 Southwood Boulevard Incline Village, Nevada 89451
|
||
| Item 2(a). Name of Person Filing: | ||
|
This report on Schedule 13G (this “Schedule 13G”) is being jointly filed by (i) Park West Asset Management LLC, a Delaware limited liability company (“PWAM”), and (ii) Peter S. Park (“Mr. Park” and, collectively with PWAM, the “Reporting Persons”).
|
||
| Item 2(b). Address of Principal Business Office or, if None, Residence: | ||
|
The address for the Reporting Persons is: 900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939.
|
||
| Item 2(c). Citizenship: | ||
|
PWAM is organized under the laws of the State of Delaware. Mr. Park is a citizen of the United States.
|
||
| Item 2(d). Title of Class of Securities: | ||
| Common Stock, $0.01 par value per share (the “Common Stock”). | ||
| Item 2(e). CUSIP No.: | ||
| 69329Y104 | ||
| Item 3. If This Statement Is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a: | ||
| Not Applicable. | ||
|
Item 4. Ownership: As reported in the cover pages to this report, the ownership information with respect to each of PWAM and Mr. Park is as follows: |
|||||
| (a) | Amount Beneficially Owned: | 5,793,497* | |||
| (b) | Percent of Class: | 5.1%* | |||
| (c) | Number of Shares as to which such person has: | ||||
| (i) | sole power to vote or to direct the vote: | 0* | |||
| (ii) | shared power to vote or to direct the vote: | 5,793,497* | |||
| (iii) | sole power to dispose or to direct the disposition of: | 0* | |||
| (iv) | shared power to dispose or to direct the disposition of: | 5,793,497* | |||
* PWAM is the investment manager to PWIMF and Park West Partners International, Limited, a Cayman Islands exempted company (collectively, the “PW Funds”). Mr. Park is the sole member and manager of PWAM. As of the date of this filing, PWAM and Mr. Park may be deemed to beneficially own 5,793,497 shares of Common Stock held in the aggregate by the PW Funds.
The reported beneficial ownership percentage is based upon 113,982,229 shares of Common Stock issued and outstanding as of July 31, 2020, based on information reported by the Company in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2020.
| Item 5. Ownership of Five Percent or Less of a Class: | |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ] | |
| Item 6. Ownership of More Than Five Percent on Behalf of Another Person: | |
| Not Applicable. | |
| Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: | |
| Not Applicable. | |
| Item 8. Identification and Classification of Members of the Group: | |
| Not Applicable. | |
| Item 9. Notice of Dissolution of Group: | |
| Not Applicable. | |
| Item 10. Certification: | |
| By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. | |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| August 28, 2020 | |||
| PARK WEST ASSET MANAGEMENT LLC | |||
| By: | /s/ Grace Jimenez | ||
| Name: Grace Jimenez | |||
| Title: Chief Financial Officer | |||
| /s/ Peter S. Park | ||||
| Peter S. Park | ||||
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001)
Exhibit Index
Exhibit
1. Joint Filing Agreement, dated as of August 28, 2020, by and between Park West Asset Management LLC and Peter S. Park.
Exhibit 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of common stock, par value $0.01 per share, of PDL Biopharma, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as Exhibit 1 to such Schedule 13G. In evidence thereof, the undersigned hereby execute this agreement this 28th day of August, 2020.
| PARK WEST ASSET MANAGEMENT LLC | |||
| By: | /s/ Grace Jimenez | ||
| Name: Grace Jimenez | |||
| Title: Chief Financial Officer | |||
| /s/ Peter S. Park | ||||
| Peter S. Park | ||||